Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients. Issue 4 (1st May 2016)

• Record Type: Journal Article
• Authors: Schmidt, Ana-Maria; Imesch, Patrick; Fink, Daniel; Egger, Herwig
• Is Part Of: International journal of gynecological cancer. Volume 26:Issue 4(2016)
• Page Start: 716
• Page End: 721
• Publication Date: 2016-05-01
• Subjects: pelvic exenteration -- endometrial cancer -- survival -- radical surgery; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000678
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: The aim of this study was to analyze the clinical experience and outcome of patients who have undergone pelvic exenteration for primary advanced or recurrent endometrial cancer. Methods: We analyzed the medical records of 40 women who underwent pelvic exenteration to treat primary advanced or recurrent endometrial cancer. Results: Pelvic exenteration was performed in 40 patients with primary advanced or recurrent endometrial cancer. Three patients (8%) underwent a primary exenteration, and 37 patients (92%) underwent a secondary exenteration. A total exenteration, anterior exenteration, and posterior exenteration was performed in 85%, 5%, and 10% of patients, respectively. In 31 cases, exenteration was performed with a curative aim, and in 9 cases, exenteration was performed with a palliative aim. The overall survival rates were 61.4% at 5 years and 51.1% at 10 years. For the 31 patients who underwent pelvic exenteration with a curative aim, the overall survival rates were higher than those for the entire study population and were 72.6% at 5 years and 59.4% at 10 years. For the 9 patients who underwent a palliative exenteration, the overall survival rates were 19.1% at 5 years and 0% at 10 years. This is to the best of our knowledge the biggest study of pelvic exenteration in patients with endometrial cancer. Conclusions: Our data show that pelvic exenterations are a valid therapeutic option with long-term survival in select patients.